{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:46:05Z","timestamp":1793727965606,"version":"4.6.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jpeds.2026.115057","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:37:30Z","timestamp":1772815050000},"page":"115057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial"],"prefix":"10.1016","volume":"293","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4385-5784","authenticated-orcid":false,"given":"Rolf M.F.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Dunbar Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian I.","family":"Borissoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofija","family":"Cerovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9nes","family":"Csonka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Reme\u0148ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"Beghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2026.115057_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00431-022-04750-y","article-title":"Advances in targeted therapy for pulmonary arterial hypertension in children","volume":"182","author":"Li","year":"2023","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jpeds.2026.115057_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/diseases6020038","article-title":"Pulmonary arterial hypertension: pathophysiology and treatment","volume":"6","author":"Lan","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.jpeds.2026.115057_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpeds.2026.115057_bib4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpeds.2026.115057_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11886-019-1229-2","article-title":"Management of pulmonary arterial hypertension in the pediatric patient","volume":"21","author":"Ezekian","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jpeds.2026.115057_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2025.1527281","article-title":"Burden of pulmonary arterial hypertension in children globally, regionally, and nationally (1990-2021): results from the global burden of disease study","volume":"13","author":"Deng","year":"2025","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jpeds.2026.115057_bib7","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01345-2024","article-title":"Embracing the challenges of neonatal and paediatric pulmonary hypertension","volume":"64","author":"Ivy","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpeds.2026.115057_bib8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01916-2018","article-title":"Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management","volume":"53","author":"Rosenzweig","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpeds.2026.115057_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/17512433.2024.2396119","article-title":"The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met?","volume":"17","author":"Wacker","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2026.115057_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhlto.2024.100152","article-title":"Circulating biomarkers in pulmonary arterial hypertension: state-of-the-art review and future directions","volume":"6","author":"Ahmed","year":"2024","journal-title":"JHLT Open"},{"key":"10.1016\/j.jpeds.2026.115057_bib21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2026.115057_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/1753466618823440","article-title":"Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience","volume":"13","author":"Belge","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jpeds.2026.115057_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40272-025-00692-8","article-title":"Macitentan: pediatric first approval","volume":"27","author":"Keam","year":"2025","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jpeds.2026.115057_bib25","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/jcph.888","article-title":"Pharmacokinetics of macitentan in patients with pulmonary arterial hypertension and comparison with healthy subjects","volume":"57","author":"Issac","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2026.115057_bib26","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni","year":"2003","journal-title":"Ambul Pediatr"},{"key":"10.1016\/j.jpeds.2026.115057_bib28","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1017\/S0950268813002471","article-title":"Incidence of acute respiratory infections in Australia","volume":"142","author":"Chen","year":"2014","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jpeds.2026.115057_bib29","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/ppul.25777","article-title":"Health-related quality of life and parental depression in children with pulmonary arterial hypertension","volume":"57","author":"Canbeyli","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jpeds.2026.115057_bib30","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00124-2020","article-title":"EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study","volume":"57","author":"Lewis","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jpeds.2026.115057_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12931-024-02994-w","article-title":"Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies","volume":"25","author":"Reinders","year":"2024","journal-title":"Respir Res"},{"key":"10.1016\/j.jpeds.2026.115057_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ehjqcco\/qcad020","article-title":"Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry","volume":"10","author":"Ploegstra","year":"2024","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jpeds.2026.115057_bib33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40272-023-00573-y","article-title":"Macitentan in the young-mid-term outcomes of patients with pulmonary hypertensive vascular disease treated in a pediatric tertiary care center","volume":"25","author":"Albinni","year":"2023","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.jpeds.2026.115057_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020979503","article-title":"Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues - a single-centre experience","volume":"11","author":"Albinni","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jpeds.2026.115057_bib35","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1017\/S1047951120000773","article-title":"Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results","volume":"30","author":"Aypar","year":"2020","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jpeds.2026.115057_bib36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1017\/S1047951117002542","article-title":"Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension","volume":"28","author":"Aypar","year":"2018","journal-title":"Cardiol Young"},{"key":"10.1016\/j.jpeds.2026.115057_bib37","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.21037\/cdt.2020.04.01","article-title":"Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension","volume":"10","author":"Schweintzger","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.jpeds.2026.115057_bib40","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/bcp.13267","article-title":"A Bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: future-3","volume":"83","author":"Berger","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2026.115057_bib41","article-title":"A randomized study of safety and efficacy of two doses of Ambrisentan to treat pulmonary arterial hypertension in pediatric patients aged 8 years up to 18 years","volume":"5","author":"Ivy","year":"2020","journal-title":"J Pediatr X"},{"key":"10.1016\/j.jpeds.2026.115057_bib42","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jcph.2199","article-title":"Pediatric population pharmacokinetic modeling and exposure-response analysis of ambrisentan in pulmonary arterial hypertension and comparison with adult data","volume":"63","author":"Okour","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2026.115057_bib43","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","article-title":"The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist","volume":"55","author":"Bolli","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpeds.2026.115057_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047662","article-title":"Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells","volume":"7","author":"Gatfield","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jpeds.2026.115057_bib45","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347626000855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347626000855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:24:48Z","timestamp":1779481488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347626000855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S0022347626000855"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2026.115057","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2026.115057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115057"}}